<table data-role="table" id="table2" data-mode="columntoggle" class="ui-responsive table-stroke">
<tbody>
<tr>
<td>Clinicians should discuss PrEP with the following non-HIV-infected individuals who have substantial and ongoing risk:<p></p>
<ul class="single">
<li><strong>Men who have sex with men (MSM)</strong> who engage in unprotected anal intercourse
	(<font class="ref">references:
    <a href="references.jsp?ref=Smith" data-inline="true" data-rel="dialog" data-transition="<%=transition%>" class="reference">Smith DK et al, 2012</a>,
    <a href="references.jsp?ref=Grov" data-inline="true" data-rel="dialog" data-transition="<%=transition%>" class="reference">Grov C et al, 2013</a></font>)
</li>
<li>Individuals who are in a <strong>serodiscordant sexual relationship</strong> with a known HIV-infected partner</li>
<li>Male-to-female and female-to male <strong>transgender individuals</strong> engaging in high-risk sexual behaviors</li>
<li>Individuals engaging in <strong>transactional sex,</strong> such as sex for money, drugs, or housing</li>
<li><strong>Injection drug users</strong> who report any of the following behaviors: sharing injection equipment (including to inject hormones among transgender individuals), injecting one or more times per day, injecting cocaine or methamphetamine, 
	engaging in high-risk sexual behaviors (<font class="ref"><a href="references.jsp?ref=Choopanya" data-inline="true" data-rel="dialog" data-transition="<%=transition%>" class="reference">reference:
    Choopanya K et al, 2013</a>
    </font>)

</li>
<li>Individuals who use <strong>stimulant drugs associated with high-risk behaviors,</strong> such as methamphetamine
	(<font class="ref">references:
    <a href="references.jsp?ref=Smith" data-inline="true" data-rel="dialog" data-transition="<%=transition%>" class="reference">Smith DK et al, 2012</a>,
    <a href="references.jsp?ref=Grov" data-inline="true" data-rel="dialog" data-transition="<%=transition%>" class="reference">Grov C et al, 2013</a>,
    <a href="references.jsp?ref=Menza" data-inline="true" data-rel="dialog" data-transition="<%=transition%>" class="reference">Menza TW et al, 2009</a>,
    <a href="references.jsp?ref=Buchacz" data-inline="true" data-rel="dialog" data-transition="<%=transition%>" class="reference">Buchacz K et al, 2005</a>,
    <a href="references.jsp?ref=Zule " data-inline="true" data-rel="dialog" data-transition="<%=transition%>" class="reference">Zule WA et al, 2007</a></font>)
	

</li>
<li>Individuals diagnosed with more than one anogenital <strong>sexually transmitted infection</strong> 
	in the last year (<font class="ref"><a href="references.jsp?ref=Menza" data-inline="true" data-rel="dialog" data-transition="<%=transition%>" class="reference">reference: Menza TW et al, 2009</a></font>)


</li>
<li>Individuals who have been prescribed <a href="http://www.hivguidelines.org/clinical-guidelines/post-exposure-prophylaxis/hiv-prophylaxis-following-non-occupational-exposure/" target="_blank">non-occupational post-exposure prophylaxis</a> (nPEP) who demonstrate continued high-risk behavior or have used multiple courses of nPEP
	(<font class="ref"><a href="references.jsp?ref=Heuker" data-inline="true" data-rel="dialog" data-transition="<%=transition%>" class="reference">reference: Heuker J et al, 2012</a></font>)
</li>
</ul>
</td>
</tr>
</tbody>
</table>